http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0344396-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b502fde933db1d6126d10bbcbddb83ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e9445e5e3626f36e932c6451a928250
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-38
filingDate 1990-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec393dec0f865ac6cc950698c1cd6997
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1acce0d335537b4279f5c5a5866ea87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91f64a5cf9904956e1088dc05a738351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4432711806d2c7c22c09cd091101f896
publicationDate 1991-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-H0344396-A
titleOfInvention Topical formulation
abstract PURPOSE: To provide the subject topically administrable preparation containing a specific methanediphosphonic acid deriv. and useful for treating hypercalcemia and an osteolytic bone transfer disease and easily carried via the skin to immediately act on the whole body. n CONSTITUTION: The objective preparation pref. contains 0.5-5% of a methanediphosphonic acid deriv. represented by the formula (wherein R 1 and R 2 are each H or 1-3C alkyl) and its salt (e.g.; 3-amino-1-hydroxypropane-1,1- diphosphonic acid). This preparation is pref. used in a form of cream, gel, an ointment, lotion, paste, froth, tinctura, a microemulsion or a soln. n COPYRIGHT: (C)1991,JPO
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11077194-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10828323-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10912743-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10206947-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10226483-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010510194-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015509982-A
priorityDate 1989-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411029050
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503883
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16124
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4674

Total number of triples: 40.